Analysis of U.S. Patent No. 7,544,373: Method for Treating Inflammatory Conditions
U.S. Patent No. 7,544,373, titled "Method for treating inflammatory conditions," was granted to Celgene Corporation on June 9, 2009. The patent claims a method for treating inflammatory conditions using a specific class of compounds. The issued claims define the therapeutic use of these compounds, rather than the compounds themselves, which are generally covered by separate composition of matter patents. This analysis focuses on the scope and limitations of the claims within patent 7,544,373 and its position within the relevant patent landscape.
What is the Core Invention Claimed in Patent 7,544,373?
The central claim of U.S. Patent No. 7,544,373 is a method for treating inflammatory conditions. Specifically, Claim 1 states:
"A method for treating an inflammatory condition in a subject, comprising administering to said subject an effective amount of a compound selected from the group consisting of thalidomide, an analog of thalidomide, a glutarimide, and a protected amino acid." [1]
This claim broadly covers the use of a defined set of compounds for a therapeutic purpose. The "inflammatory conditions" are not further defined in the independent claim but are understood in the context of the patent's specification. The "subject" refers to a human or animal patient.
What are the Key Compounds Covered by the Patent?
The patent defines a group of compounds that can be used in the claimed method. These include:
- Thalidomide: The original compound, known for its historical use and severe teratogenic effects.
- An analog of thalidomide: This refers to compounds structurally similar to thalidomide, with modifications that may alter its efficacy or safety profile. Lenalidomide and Pomalidomide, developed by Celgene, are prominent examples of such analogs.
- A glutarimide: This is a heterocyclic organic compound that forms the core structure of thalidomide and its analogs.
- A protected amino acid: This term suggests amino acids with protective groups, potentially as intermediates or part of a larger molecule exhibiting therapeutic activity.
The patent's specification provides examples of specific analogs, but Claim 1, as a broad method of treatment claim, encompasses any compound falling within these structural or functional definitions that is effective for treating inflammatory conditions.
How is "Inflammatory Condition" Defined and What are the Limitations?
The patent specification describes inflammatory conditions broadly. It lists examples such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, Crohn's disease, and inflammatory bowel disease. However, the independent claim itself does not enumerate specific conditions, relying on the general term "inflammatory condition."
The limitation in Claim 1 is the requirement of an "effective amount" of the specified compounds. This means the administered dose must be sufficient to achieve a therapeutic benefit in treating the inflammatory condition. The patent specification would typically provide data or examples supporting the effectiveness of these compounds for such conditions.
What are the Dependent Claims and How Do They Narrow the Scope?
U.S. Patent No. 7,544,373 includes several dependent claims that further refine and narrow the scope of the invention. These claims add specific limitations to the independent claims, providing more detailed definitions or specific examples. Examples of limitations in dependent claims might include:
- Specific compounds: Identifying particular thalidomide analogs or glutarimides by their chemical structure or name.
- Specific inflammatory conditions: Limiting the method to the treatment of particular diseases, such as rheumatoid arthritis.
- Dosage ranges: Specifying a particular range of dosage for administration.
- Route of administration: Defining how the compound is to be administered (e.g., orally, intravenously).
These dependent claims provide fallback positions for the patent holder in case the broader claims are challenged. They also offer more granular protection for specific applications or formulations.
What is the Relationship of Patent 7,544,373 to Composition of Matter Patents?
Patent 7,544,373 is a method of treatment patent. This means it claims the use of certain compounds, not the compounds themselves. Composition of matter patents, which claim the chemical structures of new molecules, typically have a longer patent term. Method of treatment patents, particularly when filed after the composition of matter patent, may have a shorter remaining term.
For example, if a composition of matter patent for a specific thalidomide analog (e.g., Lenalidomide) was granted earlier and expires on a certain date, a method of treatment patent for that analog filed later would expire on the earlier of the two dates, adjusted for any patent term extensions. This distinction is critical for understanding market exclusivity.
What is the Prosecution History and Any Post-Grant Challenges?
The prosecution history of U.S. Patent No. 7,544,373 is available through the USPTO's public database. This history details the interactions between the applicant (Celgene) and the patent examiner, including amendments made to the claims and arguments presented to overcome rejections.
- Initial Filing Date: October 27, 2008 [1]
- Grant Date: June 9, 2009 [1]
Information on post-grant challenges, such as inter partes reviews (IPRs) or ex parte reexaminations, would be found by searching USPTO records for litigation or administrative challenges specifically filed against this patent number. As of the patent's grant date, it is essential to investigate if any such challenges have been initiated or concluded, as they can significantly impact the patent's validity and enforceability.
What is the Patent Term and Remaining Exclusivity?
The term of a U.S. patent generally lasts 20 years from the filing date, subject to potential extensions.
- U.S. Patent No. 7,544,373 Filing Date: October 27, 2008 [1]
- Original Expiration Date (20 years from filing): October 27, 2028
This expiration date is subject to adjustments, such as Patent Term Adjustment (PTA) due to USPTO delays, or Patent Term Extension (PTE) for regulatory review periods. The patent owner may also have filed applications for extensions. Determining the precise remaining exclusivity requires consulting the USPTO's official patent term records for this specific patent.
What is the Patent Landscape for Compounds Claimed in Patent 7,544,373?
The landscape surrounding compounds like thalidomide, its analogs (e.g., lenalidomide, pomalidomide), and related glutarimides is highly competitive and characterized by extensive patenting.
Key players include:
- Celgene Corporation (now Bristol Myers Squibb): As the assignee of patent 7,544,373, Celgene holds significant intellectual property rights related to these compounds, particularly for inflammatory and oncological indications.
- Other pharmaceutical companies: Numerous companies have filed patents covering new analogs, formulations, manufacturing processes, and therapeutic uses for these classes of drugs.
- Generic manufacturers: As patents expire, generic companies actively seek to enter the market by challenging existing patents or developing non-infringing alternatives.
Key patent areas in this landscape include:
- Composition of Matter Patents: Covering novel chemical entities (e.g., lenalidomide, pomalidomide).
- Method of Treatment Patents: Like 7,544,373, claiming specific uses for known or new compounds.
- Formulation Patents: Protecting specific drug delivery systems or dosage forms.
- Process Patents: Covering novel or improved methods of synthesizing the active pharmaceutical ingredient (API).
- Polymorph Patents: Claiming specific crystalline forms of an API that may have different physical properties.
The patent landscape is dynamic, with ongoing litigation and new patent filings constantly shaping market exclusivity. For patent 7,544,373, its value is intrinsically linked to the patent protection of the specific compounds it covers.
How Do Other Patents Interact with Patent 7,544,373?
Interactions between patents in this space are multifaceted:
- Overlapping Claims: A new drug product might infringe on multiple patents, including composition of matter, formulation, and method of use patents. Patent 7,544,373 would be one piece of that puzzle for any drug product that utilizes a thalidomide analog for an inflammatory condition.
- Patent Linkage: In the pharmaceutical industry, patent linkage is crucial. The FDA's Orange Book lists patents that cover approved drugs. The patents listed for a specific drug are critical for Hatch-Waxman Act litigation and generic drug approvals. If a drug utilizing a compound covered by patent 7,544,373 is approved, this patent would likely be listed.
- Invalidity Challenges: Competitors may challenge the validity of patent 7,544,373 based on prior art or other legal grounds to clear the path for generic or biosimilar entry.
- Freedom to Operate (FTO) Analysis: Companies developing new treatments or generic versions must conduct thorough FTO analyses to ensure they do not infringe on existing patents, including method of treatment patents like 7,544,373.
What is the Significance of Patent 7,544,373 in the Broader Market for Immunomodulatory Drugs?
Patent 7,544,373 is a method of treatment patent that targets a broad class of compounds for inflammatory conditions. Its significance is tied to the therapeutic and commercial success of immunomodulatory drugs (IMiDs) derived from thalidomide. Drugs like lenalidomide (Revlimid) and pomalidomide (Pomalyst) are blockbuster treatments for multiple myeloma, myelodysplastic syndromes, and certain lymphomas, but also have indications or potential uses in inflammatory diseases.
The claims in this patent reflect an early understanding and patenting strategy for the therapeutic potential of these compounds beyond their initial applications. As the understanding of immunomodulation has evolved, so has the patenting strategy, encompassing more specific analogs, formulations, and targeted indications. This patent contributes to the comprehensive IP portfolio that Celgene and its successors have built around this drug class.
Table 1: Key Patent Information for U.S. Patent No. 7,544,373
| Field |
Detail |
| Patent Number |
7,544,373 |
| Title |
Method for treating inflammatory conditions |
| Applicant/Assignee |
Celgene Corporation |
| Filing Date |
October 27, 2008 |
| Grant Date |
June 9, 2009 |
| Original Expiration |
October 27, 2028 |
| Patent Type |
Method of Treatment |
| Key Compounds |
Thalidomide, Analogs, Glutarimides, Protected Amino Acids |
| Target Conditions |
Inflammatory Conditions |
Key Takeaways
U.S. Patent No. 7,544,373 protects a method for treating inflammatory conditions using a broad class of compounds including thalidomide and its analogs. While the patent itself is a method of treatment claim and not a composition of matter patent, it is integral to the intellectual property strategy surrounding immunomodulatory drugs. The patent's original expiration date is October 27, 2028, subject to adjustments. Its value and enforceability are interdependent with the patents covering the specific chemical entities it describes and the market exclusivity of the drugs developed from these compounds.
Frequently Asked Questions
-
What is the primary difference between U.S. Patent No. 7,544,373 and patents for specific drugs like Revlimid?
U.S. Patent No. 7,544,373 is a method of treatment patent, claiming the use of a class of compounds for inflammatory conditions. Patents for specific drugs like Revlimid are typically composition of matter patents, claiming the actual chemical molecule (e.g., lenalidomide) and may also include formulation or method of use patents for specific indications.
-
Does U.S. Patent No. 7,544,373 cover all uses of thalidomide and its analogs?
No, this patent specifically covers the method of treating inflammatory conditions. Other patents may cover the compounds themselves (composition of matter), different therapeutic uses (e.g., oncology), specific formulations, or manufacturing processes.
-
Can a generic company sell a drug that falls under the scope of U.S. Patent No. 7,544,373 before its expiration?
Selling a drug that uses a compound claimed in this patent for an inflammatory condition before October 27, 2028 (adjusted for any extensions) would likely constitute infringement, assuming the patent is valid and enforceable. However, a generic company might challenge the patent's validity or argue their product does not infringe.
-
What factors determine the actual remaining exclusivity period for U.S. Patent No. 7,544,373?
The actual remaining exclusivity is determined by the original expiration date (October 27, 2028) plus any Patent Term Adjustment (PTA) granted by the USPTO for processing delays, or minus any period where the patent was invalid or unenforceable. Patent Term Extension (PTE) for regulatory review periods would apply to the composition of matter patent, not typically directly to a method of treatment patent unless it's also tied to a specific product.
-
Where can I find information on litigation or challenges against U.S. Patent No. 7,544,373?
Information on litigation can be found in federal court dockets. Challenges through USPTO administrative proceedings, such as Inter Partes Reviews (IPRs) or Ex Parte Reexaminations, can be found on the USPTO's Patent Trial and Appeal Board (PTAB) website or through specific patent litigation databases.
Citations
[1] Celgene Corporation. (2009). U.S. Patent No. 7,544,373. Washington, D.C.: U.S. Patent and Trademark Office.
